FOLH1 and neoplasm: This may be explained by a lower tumour absorbed dose during [177Lu]Lu-PSMA-617 RLT in lesions with low PSMA expression, as well as potential differences in tumour biology reflected by the descriptive imaging phenotypes, which are currently not fully understood.